Trials / Terminated
TerminatedNCT02352831
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tosedostat | |
| DRUG | Capecitabine | |
| PROCEDURE | Fresh tissue biopsy | Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain. |
Timeline
- Start date
- 2015-08-31
- Primary completion
- 2017-10-20
- Completion
- 2018-10-19
- First posted
- 2015-02-02
- Last updated
- 2019-08-28
- Results posted
- 2018-12-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02352831. Inclusion in this directory is not an endorsement.